$205.91
3.93%
Nasdaq, Sep 05, 10:00 pm CET
ISIN
US04351P1012
Symbol
ASND

Ascendis Pharma A/S Sponsored ADR Stock price

$205.91
+19.32 10.35% 1M
+50.05 32.11% 6M
+68.24 49.57% YTD
+86.91 73.03% 1Y
+117.47 132.82% 3Y
+65.57 46.72% 5Y
+186.14 941.74% 10Y
+187.08 993.52% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
+7.78 3.93%
ISIN
US04351P1012
Symbol
ASND
Industry

Key metrics

Basic
Market capitalization
$12.0b
Enterprise Value
$12.3b
Net debt
$349.9m
Cash
$579.1m
Shares outstanding
61.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
20.9 | 14.0
EV/Sales
21.5 | 14.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.0%
Return on Equity
357.7%
ROCE
-160.9%
ROIC
-208.4%
Debt/Equity
-4.2
Financials (TTM | estimate)
Revenue
$575.2m | $858.3m
EBITDA
$-270.4m | $-213.6m
EBIT
$-288.4m | $-177.4m
Net Income
$-317.8m | $-239.3m
Free Cash Flow
$-200.3m
Growth (TTM | estimate)
Revenue
54.5% | 101.4%
EBITDA
32.5% | 31.1%
EBIT
30.4% | 45.7%
Net Income
44.6% | 46.0%
Free Cash Flow
48.5%
Margin (TTM | estimate)
Gross
84.9%
EBITDA
-47.0% | -24.9%
EBIT
-50.1%
Net
-55.3% | -27.9%
Free Cash Flow
-34.8%
More
EPS
$-5.0
FCF per Share
$-3.3
Short interest
4.9%
Employees
1k
Rev per Employee
$420.0k
Show more

Is Ascendis Pharma A/S Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Ascendis Pharma A/S Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

22x Buy
96%
1x Hold
4%

Analyst Opinions

23 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

Buy
96%
Hold
4%

Financial data from Ascendis Pharma A/S Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
575 575
55% 55%
100%
- Direct Costs 87 87
62% 62%
15%
488 488
53% 53%
85%
- Selling and Administrative Expenses 408 408
31% 31%
71%
- Research and Development Expense 351 351
14% 14%
61%
-270 -270
33% 33%
-47%
- Depreciation and Amortization 18 18
33% 33%
3%
EBIT (Operating Income) EBIT -288 -288
30% 30%
-50%
Net Profit -318 -318
45% 45%
-55%

In millions USD.

Don't miss a Thing! We will send you all news about Ascendis Pharma A/S Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ascendis Pharma A/S Sponsored ADR Stock News

Neutral
GlobeNewsWire
6 days ago
COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual meeting of the American Society for Bone & Mineral Research being held in Seattle from September 5-8, 2025.
Neutral
GlobeNewsWire
11 days ago
COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time in Boston, Massachusetts.
Neutral
Seeking Alpha
about one month ago
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Jan Moller Mikkelsen - President, CEO, Member of Executive Board & Executive Director Jay Donovan Wu - Executive VP & President of Ascendis US Scott T. Smith - CFO, Executive VP & Member of Executive Board Conference Call Participants Alexander Thompson - Stifel, Nicolaus & Company, Incorp...
More Ascendis Pharma A/S Sponsored ADR News

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Head office Denmark
CEO Jan Mikkelsen
Employees 1,017
Founded 2006
Website ascendispharma.dk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today